Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
undergoing Phase 3 trials for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and other psychiatric conditions. Its other drug candidate, DT402, targets autism spectrum disorder and is undergoing Phase 2 trials. Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 Copyright: dolgachov / 123RF Stock Photo Definium Therapeutics Inc (NASDAQ:DFTX) plans to host its Investor and Analyst Day on April 22. It plans to use the event to discuss DT120 program updates as well as commercial opportunities. On February 26, Definium Therapeutics released its 2025 financial results and provided updates about its business. On the financial side, the company said it spent $117.7 million on R&D in 2025. General and administrative-related spending consumed $48.6 million. That said, the company exited 2025 with $411.6 million in cash and cash equivalents and investments. According to the management, this cash amount and expected milest
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026Business Wire
- A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Announces New Employee Inducement GrantsBusiness Wire
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- DFTX's page on the SEC website